{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:22:15Z","timestamp":1763806935105},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,11,22]],"date-time":"2007-11-22T00:00:00Z","timestamp":1195689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s15010-007-6193-x","type":"journal-article","created":{"date-parts":[[2007,11,22]],"date-time":"2007-11-22T04:02:06Z","timestamp":1195704126000},"page":"414-420","source":"Crossref","is-referenced-by-count":17,"title":["A Randomized Study of Sequential Intravenous\/Oral Moxifloxacin in Comparison to Sequential Intravenous Ceftriaxone\/Oral Cefuroxime Axetil in Patients with Hospital-Acquired Pneumonia"],"prefix":"10.1007","volume":"35","author":[{"given":"G.","family":"H\u00f6ffken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the HAP study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,11,22]]},"reference":[{"key":"6193_CR1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.153.5.8630626","volume":"153","author":"American Thoracic Society","year":"1996","unstructured":"American Thoracic Society (1996) Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, preventive strategies. A consensus statement, November 1995. Am J Respir Crit Care Med 153:1711\u20131725","journal-title":"Am J Respir Crit Care Med"},{"key":"6193_CR2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/ajrccm.153.1.8542110","volume":"153","author":"KM Cunnion","year":"1996","unstructured":"Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, Rutala WA (1996) Risk factors for nosocomial pneumonia: comparing adult critical-care populations. Am J Respir Crit Care Med 153:158\u2013162","journal-title":"Am J Respir Crit Care Med"},{"key":"6193_CR3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/01.CCM.0000050464.70382.D6","volume":"31","author":"MS Niederman","year":"2003","unstructured":"Niederman MS (2003) Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 31:608\u2013616","journal-title":"Crit Care Med"},{"key":"6193_CR4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/jhin.2002.1230","volume":"51","author":"A Harmanci","year":"2002","unstructured":"Harmanci A, Harmanci O, Akova M (2002) Hospital-acquired pneumonia: challenges and options for diagnosis and treatment. J Hosp Infect 51:160\u2013167","journal-title":"J Hosp Infect"},{"key":"6193_CR5","doi-asserted-by":"crossref","first-page":"412S","DOI":"10.1378\/chest.119.2_suppl.412S","volume":"119","author":"S Fiel","year":"2001","unstructured":"Fiel S (2001) Guidelines and critical pathways for severe hospital-acquired pneumonia. Chest 119:412S\u2013418S","journal-title":"Chest"},{"key":"6193_CR6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/AAC.48.2.638-640.2004","volume":"48","author":"M Leone","year":"2004","unstructured":"Leone M, Albanese J, Sampol-Manos E, Simon N, Lacarelle B, Bruguerolle B, Martin C (2004) Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother 48:638\u2013640","journal-title":"Antimicrob Agents Chemother"},{"key":"6193_CR7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1086\/498149","volume":"41","author":"T Welte","year":"2005","unstructured":"Welte T, Petermann W, Sch\u00fcrmann D, Bauer TT, Reimnitz P, MOXIRAPID Study Group (2005) Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 41:1697\u20131705","journal-title":"Clin Infect Dis"},{"key":"6193_CR8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jemermed.2004.02.023","volume":"27","author":"E Katz","year":"2004","unstructured":"Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S (2004) Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 27:395\u2013405","journal-title":"J Emerg Med"},{"key":"6193_CR9","unstructured":"EMEA. Committee for proprietary medicinal products (CPMP): Note on guidance on evaluation of medicinal products indicated for treatment of bacterial infections. 2004. http:\/\/www.emea.europa.eu\/pdfs\/human\/ewp\/055895en.pdf"},{"key":"6193_CR10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society","year":"2005","unstructured":"American Thoracic Society (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388\u2013416","journal-title":"Am J Respir Crit Care Med"},{"key":"6193_CR11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/14656566.2.2.317","volume":"2","author":"JM Blondeau","year":"2001","unstructured":"Blondeau JM, Hansen GT (2001) Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Expert Opin Pharmacother 2:317\u2013335","journal-title":"Expert Opin Pharmacother"},{"key":"6193_CR12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/thorax.55.12.1033","volume":"55","author":"A Torres","year":"2000","unstructured":"Torres A, Bauer TT, Leon-Gil C, Castillo F, Alvarez-Lerma F, Martinez-Pellus A, Leal-Noval SR, Nadal P, Palomar M, Blanquer J, Ros F (2000) Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem\/cilastatin. Thorax 55:1033\u20131039","journal-title":"Thorax"},{"key":"6193_CR13","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1128\/AAC.46.6.1746-1754.2002","volume":"46","author":"R Finch","year":"2002","unstructured":"Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, Izquierdo JL, Nikolaides P, Ogundare F, Raz R, Zuck P, Hoeffken G (2002) Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with communityacquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 46:1746\u20131754","journal-title":"Antimicrob Agents Chemother"},{"key":"6193_CR14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/00003495-200262070-00005","volume":"62","author":"HM Lamb","year":"2002","unstructured":"Lamb HM, Ormrod D, Scott LJ, Figgitt DP (2002) Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 62:1041\u20131089","journal-title":"Drugs"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-007-6193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-007-6193-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-007-6193-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T13:37:41Z","timestamp":1559482661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-007-6193-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,22]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["6193"],"URL":"https:\/\/doi.org\/10.1007\/s15010-007-6193-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"type":"print","value":"0300-8126"},{"type":"electronic","value":"1439-0973"}],"subject":[],"published":{"date-parts":[[2007,11,22]]}}}